Durand P Y, Chanliau J, Gamberoni J, Hestin D, Kessler M
ALTIR, CHRU Nancy, France.
Adv Perit Dial. 1996;12:167-70.
We performed a cross-sectional study to establish the hepatitis C virus (HCV) serologic status for all French patients undergoing peritoneal dialysis (PD) on January 1, 1995. We listed a total of 1508 patients, and the exhaustiveness rate was about of 75% of the whole French PD population treated at this date. Only 47 of the 1508 patients were anti-HCV positive (HCV+): the global HCV prevalence was 3.12%. HCV+ patients were treated by PD for a longer time than HCV-patients (4 +/- 4 vs 2 +/- 2 years; p < 0.001); 89% of the HCV+ patients received blood transfusions; 60% had been previously treated by hemodialysis, and 26% previously received a kidney transplantation. In 49% of the HCV+ patients, HCV antibodies were discovered before the start of the peritoneal dialysis program, and a seroconversion was observed in only 4 (0.27%) of them during the PD treatment. All these patients received blood transfusion. In patients without past history of hemodialysis or transplantation (exclusively treated by PD), HCV prevalence was 1.5%, not far off that of the general population. Peritoneal dialysis seems not to be an additional risk factor for hepatitis C infection in France.
1995年1月1日，我们开展了一项横断面研究，以确定所有接受腹膜透析（PD）的法国患者的丙型肝炎病毒（HCV）血清学状态。我们列出了总共1508名患者，详尽率约为此日接受治疗的法国腹膜透析患者总数的75%。1508名患者中只有47名抗-HCV呈阳性（HCV+）：总体HCV患病率为3.12%。HCV+患者接受腹膜透析的时间比HCV-患者更长（4±4年对2±2年；p<0.001）；89%的HCV+患者接受过输血；60%曾接受血液透析治疗，26%曾接受肾脏移植。在49%的HCV+患者中，HCV抗体在腹膜透析项目开始前就已被发现，在腹膜透析治疗期间仅4例（0.27%）出现血清转化。所有这些患者都接受过输血。在没有血液透析或移植病史（仅接受腹膜透析治疗）的患者中，HCV患病率为1.5%，与普通人群的患病率相差不大。在法国，腹膜透析似乎不是丙型肝炎感染的额外危险因素。
